April 3, 2017 / 11:17 AM / 7 months ago

BRIEF-Sierra Oncology reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

April 3 (Reuters) - Sierra Oncology Inc:

* Sierra Oncology Inc - Sierra Oncology collaborator ICR reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

* Sierra Oncology Inc - data supports genetically-driven clinical development strategy Sierra intends to pursue for sra737

* Sierra Oncology Inc - “gemcitabine is known to impair b-family DNA polymerases, further supporting rationale for its clinical combination with sra737.” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below